Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Research

Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma

Authors: Fangzhen Cai, Jianwei Li, Yanmei Zhang, Sihuai Huang, Wenbin Liu, Weifeng Zhuo, Chengzhi Qiu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Targeted drugs are the main methods of RCC treatment. However, drug resistance is common in RCC patients, in-depth study of the drug-resistant mechanism is essential.

Methods

We constructed sunitinib resistant and Twist overexpressed A498 cells, and studied its mechanisms in vitro and in vivo.

Results

In cell research, we found that either sunitinib resistance or Twist overexpression can activate Wnt/β-catenin and EMT signaling pathway, and the sunitinib resistance may work through β-catenin/TWIST/TCF4 trimer. In zebrafish research, we confirmed the similarity of Twist overexpression and sunitinib resistance, and the promoting effect of Twist overexpression on drug resistance.

Conclusions

Sunitinib resistance and Twist overexpression can activate Wnt/β-catenin signaling pathway and EMT to promote the growth and metastasis of RCC cells.
Appendix
Available only for authorised users
Literature
1.
Katoh Y, Katoh M. Comparative integromics on VEGF family members [J]. Int J Oncol. 2006;28(6):1585–9.PubMed
2.
Sakaguchi T, Yoshino H, Sugita S, et al. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma [J]. Oncotarget. 2018;9(33):23003–17.CrossRefPubMedPubMedCentral
3.
Ho JY, Hsu RJ, Wu CL et al. Ovatodiolide Targets beta -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma [J]. Evid Based Complement Alternat Med, 2013, 2013:161628.
4.
Ruan H, Li S, Bao L, et al. Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma [J]. Oncogene. 2020;39(38):6113–28.CrossRefPubMedPubMedCentral
5.
Muralidhar S, Filia A, Nsengimana J, et al. Vitamin D-VDR signaling inhibits Wnt/beta-Catenin-mediated Melanoma Progression and promotes Antitumor immunity [J]. Cancer Res. 2019;79(23):5986–98.CrossRefPubMed
6.
Li Q, Lai Q, He C, et al. RUNX1 promotes tumour metastasis by activating the Wnt/beta-catenin signalling pathway and EMT in colorectal cancer [J]. J Exp Clin Cancer Res. 2019;38(1):334.CrossRefPubMedPubMedCentral
7.
Teng J, Wang X, Xu Z, et al. HBx-dependent activation of twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells [J]. J Cell Biochem. 2013;114(5):1097–104.CrossRefPubMed
8.
Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells [J]. Oncogene. 2004;23(2):474–82.CrossRefPubMed
9.
Gong LG, Shi JC, Shang J, et al. Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt/beta-catenin signaling pathway [J]. Eur Rev Med Pharmacol Sci. 2019;23(3):1151–7.PubMed
10.
Khan MI, Czarnecka AM, Lewicki S, et al. Comparative gene expression profiling of primary and metastatic renal cell Carcinoma Stem Cell-Like Cancer cells [J]. PLoS ONE. 2016;11(11):e0165718.CrossRefPubMedPubMedCentral
11.
12.
Park KY, Kim J. Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-beta1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells [J]. PLoS ONE. 2020;15(8):e0232917.CrossRefPubMedPubMedCentral
13.
Shi ZM, Wang L, Shen H, et al. Downregulation of miR-218 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling [J]. Oncogene. 2017;36(18):2577–88.CrossRefPubMedPubMedCentral
14.
15.
16.
Peng F, Zhang H, Du Y, et al. miR-23a promotes cisplatin chemoresistance and protects against cisplatin-induced apoptosis in tongue squamous cell carcinoma cells through twist [J]. Oncol Rep. 2015;33(2):942–50.CrossRefPubMed
17.
Liu L, Zhu H, Liao Y, et al. Inhibition of Wnt/beta-catenin pathway reverses multi-drug resistance and EMT in Oct4(+)/Nanog(+) NSCLC cells [J]. Biomed Pharmacother. 2020;127:110225.CrossRefPubMed
18.
Suknuntha K, Thita T, Togarrati PP, et al. Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines [J]. Int J Hematol. 2017;105(2):196–205.CrossRefPubMed
19.
Maxeiner S, Grolleman J, Schmid T et al. The hypoxia-response pathway modulates RAS/MAPK-mediated cell fate decisions in Caenorhabditis elegans [J]. Life Sci Alliance, 2019, 2(3): e2019.
20.
Wang H, Zhang R, Wu X, et al. The wnt signaling pathway in Diabetic Nephropathy [J]. Front Cell Dev Biol. 2021;9:701547.CrossRefPubMed
21.
Zhang L, Zeng S, Yu Z et al. Overexpression of Activating Transcription Factor-2 (ATF-2) Activates Wnt/Ca(2+) Signaling Pathways and Promotes Proliferation and Invasion in Non-Small-Cell Lung Cancer [J]. Dis Markers, 2022, 2022:5772089.
22.
Supsavhad W, Hassan BB, Simmons JK, et al. Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK inhibitor, on wnt signaling in canine prostate Cancer growth and bone metastases [J]. Vet Sci. 2021;8(8):153.PubMedPubMedCentral
23.
Ito K, Lim AC, Salto-Tellez M, et al. RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis [J]. Cancer Cell. 2008;14(3):226–37.CrossRefPubMed
24.
Huang CX, Jiang ZX, Du DY, et al. Hsa_circ_0016070/micro-340-5p Axis accelerates pulmonary arterial hypertension progression by upregulating TWIST1 transcription Via TCF4/beta-Catenin complex [J]. J Am Heart Assoc. 2022;11(14):e024147.CrossRefPubMedPubMedCentral
25.
Liu J, Shu G, Wu A, et al. TWIST1 induces proteasomal degradation of beta-catenin during the differentiation of ovarian cancer stem-like cells [J]. Sci Rep. 2022;12(1):15650.ADSCrossRefPubMedPubMedCentral
26.
Ghatak S, Hascall VC, Karamanos N, et al. Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through beta-catenin/MDR1 signaling to sustain chemoresistance [J]. Front Oncol. 2022;12:906260.CrossRefPubMedPubMedCentral
Metadata
Title
Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma
Authors
Fangzhen Cai
Jianwei Li
Yanmei Zhang
Sihuai Huang
Wenbin Liu
Weifeng Zhuo
Chengzhi Qiu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11907-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Attitudes towards risk-stratified breast cancer screening: a population-based survey among 5,001 Danish women

Research

Determination of drug-related problems in the hematology service: a prospective interventional study

Research

“How can a woman live without having a breast?”: challenges related to mastectomy in Ethiopia

Research

CNN-based multi-modal radiomics analysis of pseudo-CT utilization in MRI-only brain stereotactic radiotherapy: a feasibility study

Research

High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma

Research

Baseline knowledge on risk factors, symptoms and intended behavior of women and men towards screening and treatment of cervical cancer in rural Uganda: a cross-sectional study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits